PRESIDENT
Antonio Gasbarrini
Per l’evento sono stati assegnati
n. 7 crediti formativi E.C.M.
ID evento: 6364 – 428547
L’evento è stato accreditato per le figure di:
Biologo, Infermiere Farmacista Farmacista Pubblico Del Ssn Farmacista Territoriale Farmacista Di Altro Settore, Dietista, Medico Chirurgo (Gastroenterologia, Medicina e chirurgia di accettazione ed urgenza, Medicina interna, Chirurgia generale, Geriatria, Medicina Generale, Scienza dell’Alimentazione e dietetica)
SCIENTIFIC COORDINATORS
Franco Scaldaferri
Loris Riccardo Lopetuso
SCIENTIFIC COMMITTEE
Alessandro Armuzzi
Giovanni Cammarota
Fabio Cominelli
Sara Deleu
Gianluca Ianiro
Alfredo Papa
Theresa T. Pizarro
Maurizio Sanguinetti
Severine Vermeire
PROGRAMME
December 5th, 2024
SESSION I – MICROBIOTA, FMT IN IBD – THE ROME MEETING
Chairs: L. R. Lopetuso, F. Scaldaferri
14.00 – 14.20 Greetings and introduction to the day
A. Gasbarrini, M.Sanguinetti
14.20 – 14.40 Gut microbiota in health and disease
Herbert Tilg
14.40 – 15.00 Computational metagenomics for the analysis of gut microbiota
F. De Maio
15.00 – 15.20 Gut microbiota testing in clinical practice
G. Ianiro
15.20 – 15.40 Discussion
SESSION II Focus on Gut microbiota in IBD
Chairs: G. Cammarota, E. Savarino
15.40 – 16.00 Microbiota imbalance in IBD
S. Vermeire
16.00 – 16.20 How the microbiota shapes the immune system in health and disease
T. T. Pizarro
16.20 – 16.40 Pharmacological and non-pharmacological modulators of gut microbiota
J. Raes
16.40 – 17.00 Discussion
17.00 – 17.30 Coffee break
SESSION III Gut microbiota in IBD: target for therapies?
Chairs: F. Cominelli, S. Vermeire
17.30 – 17.50 Mesalazine and beyond: gut microbiota interference on drug activity
A. Papa
17.50 – 18.10 Gut microbiota and IBD therapeutics: anti-TNF, anti-integrin and anti-IL12/IL23 therapeutic strategies
S. Paramsothy
18.10 – 18.30 Gut microbiota and IBD therapeutics: anti-JAKs, anti-IL23 therapeutic strategies and beyond
D. Noviello
18.30 – 18.50 Gut microbiota in drug-induced inflammatory bowel diseases: towards new predictive, diagnostic and therapeutic strategies
E. Savarino
18.50 – 19.10 Discussion
December 6th, 2024
SESSION IV Gut microbiota in IBD: anything beyond available therapies?
Chairs: P. Gionchetti, L. R. Lopetuso, T. T. Pizarro
09.00 – 09.20 How diet shapes intestinal inflammation in murine models of IBD?
F. Cominelli
09.20 – 09.40 Precision nutrition and the gut microbiota
S. Deleu
09.40 – 10.00 Pre- and pro-biotics in clinical practice
G. Marasco
10.20 – 10.40 Future microbiome therapeutics
F. Facciotti
10.40 – 11.00 Discussion
11.00 – 11.30 Coffee break
SESSION V Building evidence for FMT in IBD: from trial to clinical practice
Chairs: G. Fiorino, L. Putignani, S. Vetrano
11.30 – 11.50 FMT: current evidence and future applications
J. Kupcisnskas
11.50 – 12.10 FMT in IBD: how to break the therapeutic ceiling?
I. Dotan
12.10 – 12.30 Methodological challenges in RCTs for complex therapies: Lessons for FMT Trials
D. Piovani
12.30 – 12.50 How to design future real life trials in IBD: lessons from pharmacological trials
L. Laterza
12.50 – 13.10 Results from the II Rome Consensus Conference on Gut Microbiota and FMT
F. Scaldaferri, L. R. Lopetuso
13.10 – 13.30 Discussion
13.30 – 14.30 Lunch
14.30 – 16.30 II Rome Consensus Conference on Gut Microbiota and FMT
Invited Session
SCIENTIFIC COORDINATORS:
Antonio Gasbarrini, Loris Riccardo Lopetuso, Franco Scaldaferri
EXPERT PANEL MEMBERS:
Maria Abreu, Alessandro Armuzzi, Patrizia Brigidi, Giovanni Cammarota, Fabio Cominelli, Samuel Paul Costello, Sara Deleu, Flavio De Maio, Iris Dotan, Federica Facciotti, Gionata Fiorino, Lihi Godny, Ailsa Hart, Gianluca Ianiro, Tariq H Iqbal, Dai Ishikawa, Juozas Kupcisnskas, Giovanni Marasco, Luca Masucci, Daniele Noviello, Alfredo Papa, Sudarshan Paramsothy, Valentina Petito, Theresa T. Pizarro, Pierluigi Puca, Daniela Pugliese, Lorenza Putignani, Davide Ribaldone, Maurizio Sanguinetti, Edoardo Savarino, Harry Sokol, Herbert Tilg, Séverine Vermeire
Donors profiling
Chair: L. Putignani
Discussant: S. Deleu, V. Petito
Patients profiling
Chair: A. Armuzzi
Discussant: G. Marasco, J. Raes
Trial design
Chair: S. Vermeire
Discussant: G. Fiorino, D. Piovani
Future perspectives
Chair: G. Cammarota
Discussant: L. Godny, P. Puca
